Pulike Biological Engineering (SHSE:603566) EBIT: ¥190 Mil (TTM As of Mar. 2026)


SHSE:603566 Pulike Biological Engineering Inc SHSE:603566
64 GF Score
Price ¥10.24
GF Value ¥14.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Pulike Biological Engineering EBIT?

Pulike Biological Engineering SHSE:603566 -2.94% 64 EBIT is ¥190 Mil as of Mar. 2026. GuruFocus rates SHSE:603566 with a GF Score™ of 64/100 and a GF Value™ of ¥14.18 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Pulike Biological Engineering's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥45 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥190 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pulike Biological Engineering's annualized ROC % for the quarter that ended in Mar. 2026 was 6.79%. Pulike Biological Engineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pulike Biological Engineering's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.24%.


Pulike Biological Engineering  (SHSE:603566) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pulike Biological Engineering's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=182.036 * ( 1 - 20.8% )/( (2100.907 + 2142.696)/ 2 )
=144.172512/2121.8015
=6.79 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3236.859 - 362.795 - ( 773.157 - max(0, 425.141 - 1367.307+773.157))
=2100.907

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3217.27 - 320.231 - ( 754.343 - max(0, 368.262 - 1406.478+754.343))
=2142.696

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pulike Biological Engineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=180.904/( ( (1291.87 + max(159.78, 0)) + (1264.082 + max(270.037, 0)) )/ 2 )
=180.904/( ( 1451.65 + 1534.119 )/ 2 )
=180.904/1492.8845
=12.12 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(350.673 + 219.728 + 7.5739999999998) - (362.795 + 0 + 55.4)
=159.78

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(389.709 + 230.236 + 11.541) - (320.231 + 0 + 41.218)
=270.037

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pulike Biological Engineering's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=190.302/3049.702
=6.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulike Biological Engineering EBIT Related Terms


Pulike Biological Engineering EBIT Historical Data

* Premium members only.

The historical data trend for Pulike Biological Engineering's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulike Biological Engineering EBIT Chart

Pulike Biological Engineering Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 271.09 178.45 195.54 98.85 207.40

Pulike Biological Engineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.32 62.81 45.56 36.71 45.23

SHSE:603566 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Pulike Biological Engineering's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulike Biological Engineering EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pulike Biological Engineering's EV-to-EBIT falls into.


SHSE:603566
64GF Score
Pulike Biological Engineering Inc SHSE:603566
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulike Biological Engineering EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥190 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥190 Mil mean?
Pulike Biological Engineering (SHSE:603566) has a EBIT of ¥190 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pulike Biological Engineering.
Is Pulike Biological Engineering's EBIT too high?
Pulike Biological Engineering's current EBIT is ¥190 Mil. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's EBIT compare to VRTX and REGN?
Pulike Biological Engineering's EBIT of ¥190 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pulike Biological Engineering. Pulike Biological Engineering's current EBIT is ¥190 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.18, compared to a current price of ¥10.24 — trading 27.8% below its estimated fair value. The current EBIT is ¥190 Mil. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current EBIT is ¥190 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?

Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued. The current stock price of ¥10.24 is trading 27.8% below its estimated GF Value™ of ¥14.18. GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.

Key valuation signals for SHSE:603566:

  • EBIT: ¥190 Mil
  • GF Value™: ¥14.18 vs. price of ¥10.24 (27.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pulike Biological Engineering Business Description

Address 15th New governance, Henan Province, Luoyang, CHN, 471000
Pulike Biological Engineering Inc is engaged in the research and development and production and operation of veterinary drugs.
64GF Score

Get the complete analysis for SHSE:603566

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.24
Price
¥14.18
GF Value